Drug intelligence / Profile preview

CellxLife DC Vaccine

Development stage: Unknown
Lead developer: CellxLife
Modality: Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
Administration: Intradermal

Overview

CellxLife DC Vaccine (TUVAC1) is an autologous dendritic cell-based cancer vaccine developed by CellxLife for the treatment of pediatric solid tumors, including relapsed or recurrent metastatic Ewing sarcoma and osteosarcoma. The therapy utilizes the patient's own dendritic cells, which are harvested, processed, and potentially loaded with tumor-associated antigens to stimulate a robust, tumor-specific T-cell immune response upon re-administration. Following the completion of a Phase 1 clinical trial, the program is currently being prepared for Phase 2 clinical evaluation.

Other names: TUVAC1TUVAC-1TUVAC 1CellxLife dendritic cell vaccine

Beyond the preview

Go deeper on CellxLife DC Vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CellxLife DC Vaccine.

Explore the full profile